Wichtige Dokumente

Gesamtdokumentation anzeigen

F6020

Fenofibrat

Name: Fenofibrat
Brand: SIGMA

≥99% (TLC), powder, PPARα agonist

Synonym(e):

2-[4-(4-Chlorbenzoyl)-phenoxy]-2-methyl-propansäure-isopropylester

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern

Über diesen Artikel

Empirische Formel (Hill-System):

C₂₀H₂₁ClO₄

CAS-Nummer:

49562-28-9

Molekulargewicht:

360.83

NACRES:

NA.77

PubChem Substance ID:

24278015

UNSPSC Code:

12352200

EC Number:

256-376-3

MDL number:

MFCD00133314

Assay:

≥99%

Form:

powder

Technischer Dienst

Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.

Unterstützung erhalten

Eigenschaften

Produktname

Fenofibrat, ≥99%, powder

Quality Segment

100

assay

≥99%

form

powder

color

off-white

originator

Abbott

storage temp.

room temp

SMILES string

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

InChI key

YMTINGFKWWXKFG-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)

Beschreibung

Application

Fenofibrate has been used:

to study its effect on plasma lipids, liver phenotype and gene expression
to study its impact on endothelium-dependent vasodilatation of thoracic aorta
to administer to NASH knock-in mice along with a high fat diet (HFD) to study its effect

Biochem/physiol Actions

Fenofibrate increases high density lipoprotein levels by reducing cholesteryl ester transfer protein expression. It is used in treating the condition of increased cholesterol levels in the blood, abnormal lipid levels in the body and also hypertriglyceridaemia. Fenofibrate is a lipid regulating drug and proliferator-activated receptor-α (PPARα) mediates its action. It decreases the plasma levels of fibrinogen and C-reactive protein. By this fenofibrate allows better flow-mediated dilatation and reduces the risk of atherosclerosis. Fenofibrate is also known to reduce uric acid levels.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.